Brief: Verastem To Open TARGET-D 301 1L mPDAC Trial By Year-End 2026
14/10/2026 11:11
BRIEF-Verastem To Open TARGET-D 301 1L mPDAC Trial By Year-End 2026 Oct 14 (Reuters) - Verastem Inc VSTM.O:
VERSUS-7375 DEMONSTRATES ROBUST ANTI-TUMOR ACTIVITY ACROSS ADVANCED KRAS G12D-MUTANT CANCERS, HIGHLIGHTED BY 50% CONFIRMED ORR IN 2L PANCREATIC DUCTAL ADENOCARCINOMA AND TWO COMPLETE RESPONSES IN 2L+ DISEASE (ONE CONFIRMED)
VERASTEM - TO OPEN TARGET-D 301 1L MPDAC TRIAL BY YEAR-END 2026
VERASTEM - VERSUS-7375 900 MG QD MONOTHERAPY ACHIEVES 41% CONFIRMED ORR IN 2L+ PDAC
VERASTEM INC: EXPECT TO REPORT INITIAL DATA FROM 1L MPDAC COMBINATION WITH GNP IN Q1 2027
Source text: ID:nBw3P7Hw9a
Further company coverage: VSTM.O
((Reuters.Briefs@thomsonreuters.com;))